Ergam Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-12-2024
- Paid Up Capital ₹ 1.00 M
as on 05-12-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.10 Cr
as on 05-12-2024
- Revenue -35.54%
(FY 2020)
- Profit -27.25%
(FY 2020)
- Ebitda -26.42%
(FY 2020)
- Net Worth 32.93%
(FY 2020)
- Total Assets -21.26%
(FY 2020)
About Ergam Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.10 Cr.
Ergamreddy Reddy, Ergamreddy Sandhya, and Sai Rudra serve as directors at the Company.
- CIN/LLPIN
U24233TG2016PTC103791
- Company No.
103791
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Ergam Life Sciences Private Limited offer?
Ergam Life Sciences Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Speciality Chemicals, Chemical Intermediates.
Who are the key members and board of directors at Ergam Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ergamreddy Reddy  | Managing Director | 10-Mar-2016 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sai Rudra | Additional Director | 03-Sep-2020 | Current |
| Ergamreddy Sandhya | Additional Director | 04-May-2020 | Current |
Financial Performance of Ergam Life Sciences.
Ergam Life Sciences Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 35.54% decrease. The company also saw a substantial fall in profitability, with a 27.25% decrease in profit. The company's net worth Soared by an impressive increase of 32.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ergam Life Sciences?
In 2020, Ergam Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Chahna Fabrication Works Private LimitedActive 5 years 11 months
Ergamreddy Reddy is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 May 2020 | ₹1.10 Cr | Open |
How Many Employees Work at Ergam Life Sciences?
Unlock and access historical data on people associated with Ergam Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ergam Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ergam Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
